| lapatinib + letrozole vs letrozole alone | progression or death (progression free survival PFS) by 29% (fully demonstrated) Serious adverse event by 100% (harmful effect) | | Endpoint | TE [95% CI] | p val | I2 | n | k | trials |
|---|
| objective response (ORR) | no data | | clinical benefit | no data | | progression (Time to progression TTP) | no data | | death (overall survival) | 0.78 [0.57 1.07] | p=1.00 | 0 | 1286 | 1 | Johnston (EGF30008) , | | progression or death (progression free survival PFS) | 0.71 [0.53 0.96] | p=0.04 | 0 | 1286 | 1 | Johnston (EGF30008) , | | Serious adverse event | 2.00 [1.57 2.55] | p=0.04 | 0 | 1286 | 1 | Johnston (EGF30008) , |
TE: treatment effect; CI: confidence interval; k: nulmber of trials; n: total number of patients |
| lapatinib + paclitaxel vs paclitaxel alone | No demonstrated result Serious adverse event by 65% (harmful effect) | | Endpoint | TE [95% CI] | p val | I2 | n | k | trials |
|---|
| objective response (ORR) | no data | | clinical benefit | no data | | progression (Time to progression TTP) | no data | | death (overall survival) | 0.86 [0.69 1.08] | p=1.00 | 0 | 579 | 1 | Di Leo, | | progression or death (progression free survival PFS) | 0.90 [0.75 1.08] | p=1.00 | 0 | 579 | 1 | Di Leo, | | Serious adverse event | 1.65 [1.16 2.35] | p=0.04 | 0 | 579 | 1 | Di Leo, |
TE: treatment effect; CI: confidence interval; k: nulmber of trials; n: total number of patients |
